prostat
cancer
cell
express
prostatespecif
membran
antigen
psma
target
rna
aptamersmal
interf
si
rna
chimera
therapeut
efficaci
vivo
demonstr
intratumor
inject
clinic
translat
approach
requir
chimera
effect
administ
system
amen
chemic
synthesi
end
enhanc
silenc
activ
specif
aptamersirna
chimera
incorpor
modif
enabl
effici
process
sirna
cellular
machineri
includ
ad
optim
thermodynam
profil
structur
duplex
favor
process
sirna
guid
strand
also
truncat
aptam
portion
chimera
facilit
largescal
chemic
synthesi
optim
chimera
result
pronounc
regress
psmaexpress
tumor
athym
mice
system
administr
antitumor
activ
enhanc
append
polyethylen
glycol
moieti
increas
chimera
circul
halflif
treatment
advanc
prostat
cancer
reli
mainli
nonspecif
therapi
chemotherapi
ioniz
radiat
low
efficaci
highli
toxic
normal
tissu
genespecif
mrna
knockdown
synthet
sirna
may
offer
sever
advantag
approach
includ
target
specif
eas
sirna
product
possibl
silenc
virtual
gene
addit
recent
advanc
understand
molecular
mechan
rna
interfer
rnai
enabl
ration
optim
potenc
specif
vivo
activ
sirna
howev
sirna
broadli
use
clinic
safe
effect
approach
target
deliveri
vivo
must
develop
sirna
target
approach
involv
format
sirnacontain
complex
also
includ
charg
peptid
protein
polym
although
reagent
silenc
target
gene
administ
system
experiment
anim
complic
formul
like
confound
largescal
product
regulatori
approv
potenti
toxic
materi
use
pose
anoth
challeng
result
applic
involv
direct
local
deliveri
exampl
eye
lung
nake
nucleaseresist
chemic
modifi
sirna
duplex
first
evalu
clinic
trial
previous
develop
simpl
rnaonli
approach
deliv
cytotox
sirna
target
prostat
cancerspecif
prosurviv
gene
directli
prostat
cancer
cell
via
rna
aptam
aptam
portion
chimera
bind
psma
undergo
cell
intern
deliv
sirna
cargo
intracellular
rnai
machineri
result
silenc
sirna
target
gene
pronounc
cancer
cell
death
vitro
inject
intratumor
psmatarget
chimera
substanti
decreas
tumor
volum
xenograft
mous
model
prostat
cancer
induc
apoptosi
tumor
express
psma
advers
effect
psmaneg
tumor
normal
cell
although
firstgener
psmabind
chimera
inhibit
tumor
growth
administ
intratumor
system
administr
necessari
treatment
advanc
prostat
cancer
thu
present
varieti
addit
challeng
particular
system
administr
requir
greater
therapeut
dose
lead
higher
treatment
cost
carri
greater
risk
harm
side
effect
owe
greater
therapeut
exposur
nontarget
tissu
improv
would
minim
necessari
dose
chimera
would
reduc
cost
treatment
risk
harm
side
effect
toward
end
modifi
sever
aspect
result
optim
chimera
exhibit
potent
antitumor
activ
administ
system
mice
bear
psmaposit
prostat
cancer
tumor
design
secondgener
chimera
aim
facilit
chemic
synthesi
ii
enhanc
silenc
activ
specif
iii
enabl
modif
optim
vivo
kinet
repres
secondgener
chimera
develop
studi
shown
figur
facilit
chemic
synthesi
reduc
aptam
portion
correspond
origin
aptam
nucleotid
nt
aptam
longer
rna
strand
secondgener
chimera
modifi
shorter
rna
strand
unmodifi
except
stem
loop
chimera
fulli
modifi
truncat
version
firstgener
chimera
refer
blunt
chimera
sirna
blunt
duplex
fig
ident
sirna
part
firstgener
chimera
increas
silenc
activ
specif
chimera
engin
sever
chimera
four
describ
variou
modif
sirna
portion
first
chimera
uu
overhang
end
sirna
duplex
ovh
chimera
design
favor
recognit
rnase
enzym
dicer
second
wobbl
base
pair
engin
end
guid
silenc
strand
ovh
chimera
introduc
mutat
passeng
strand
gu
wobbl
chimera
modif
intend
increas
silenc
specif
favor
load
guid
strand
rnainduc
silenc
complex
risc
third
swap
passeng
guid
fig
strand
sirna
duplex
swap
chimera
configur
intend
accommod
termin
modif
shorter
rna
strand
without
loss
function
modif
also
take
advantag
strandload
bia
introduc
interact
overhang
paz
domain
andor
dicer
configur
favor
load
guid
strand
strand
contain
overhang
risc
fourth
stem
loop
chimera
sirna
duplex
stem
continu
aptam
loop
design
mimic
endogen
mirna
precursor
test
abil
truncat
psma
aptam
bind
surfac
prostat
cancer
cell
express
psma
cell
line
lncap
clone
psmaneg
prostat
cancer
cell
line
use
control
specif
surfac
express
psma
verifi
use
flow
cytometri
data
shown
determin
whether
truncat
aptam
bind
surfac
cell
express
psma
incub
plabel
aptam
ref
nt
either
lncap
cell
fig
bind
aptam
specif
cell
express
psma
depend
region
within
truncat
rna
retain
specif
bind
psmaexpress
cell
aptam
found
bind
lncap
cell
compar
affin
fulllength
rna
aptam
fig
next
test
abil
bind
psmaexpress
cell
context
modif
sirna
part
chimera
fig
chimera
retain
bind
psmaexpress
prostat
cancer
cell
experi
confirm
modif
made
firstgener
chimera
affect
bind
target
specif
determin
whether
secondgener
chimera
silenc
target
gene
express
whether
enhanc
silenc
activ
compar
firstgener
chimera
test
genespecif
silenc
use
quantit
real
timepcr
qrtpcr
fig
psmaexpress
cell
transfect
increas
amount
nm
secondgener
chimera
use
cation
lipid
reagent
fig
control
cell
transfect
control
nonsilenc
sirna
mock
elev
express
cell
confirm
use
immunoblot
supplementari
fig
specif
cancer
cell
normal
cell
human
fibroblast
littletono
protein
supplementari
fig
modif
introduc
within
sirna
portion
chimera
enhanc
silenc
activ
secondgener
chimera
swap
stem
loop
chimera
result
silenc
concentr
low
nm
next
verifi
abil
secondgener
chimera
silenc
target
gene
express
absenc
transfect
reagent
fig
cell
incub
media
contain
variou
rna
chimera
modif
made
sirna
portion
chimera
substanti
enhanc
chimera
silenc
potenti
versu
secondgener
chimera
respect
nm
concentr
rna
without
affect
bind
psma
cell
surfac
effect
observ
psmaneg
prostat
cancer
cell
data
shown
experi
indic
secondgener
chimera
silenc
activ
time
stronger
firstgener
chimera
next
assess
whether
dicer
process
sirna
portion
chimera
context
psma
aptam
fig
plabel
chimera
label
short
rna
strand
incub
recombin
human
dicer
h
h
cleavag
product
analyz
nondenatur
gel
electrophoresi
incub
dicer
result
plabel
cleav
product
correspond
size
duplex
sirna
mer
data
suggest
rna
chimera
dicer
substrat
size
plabel
cleav
product
mer
also
indic
side
dicer
enter
chimera
cleav
result
suggest
dicer
enter
longer
rna
strand
cleav
nt
upstream
increas
level
process
duplex
secondgener
construct
compar
firstgener
chimera
suggest
may
better
substrat
dicer
next
test
whether
modif
made
sirna
portion
secondgener
chimera
affect
load
correct
sirnasilenc
strand
risc
fig
load
correct
strand
rnai
machineri
gener
sirna
increas
activ
reduc
offtarget
effect
load
risc
assess
small
fragment
northern
strandbia
assay
assay
allow
quantit
measur
guid
strand
sirna
duplex
incorpor
risc
therebi
protect
nucleas
degrad
strand
incorpor
risc
rapidli
degrad
assay
suggest
modif
made
firstgener
chimera
substanti
enhanc
load
correct
strand
risc
although
addit
uu
overhang
end
sirna
duplex
alon
enhanc
load
correct
strand
risc
incorpor
wobbl
base
end
guid
strand
effect
notabl
swap
passeng
strand
guid
strand
result
substanti
increas
load
guid
strand
risc
fig
even
greater
effect
strand
load
observ
stem
loop
chimera
passeng
guid
configur
swap
chimera
fig
togeth
data
indic
modif
made
sirna
portion
chimera
enhanc
silenc
activ
specif
promot
optim
rnai
process
deplet
cancer
cell
lead
arrest
decreas
cell
prolifer
subsequ
cancer
cell
death
due
mitot
catastroph
crisi
type
cell
death
result
mitot
dna
damag
determin
whether
treatment
variou
psma
chimera
result
reduc
cellular
prolifer
cell
transfect
chimer
rna
use
cation
lipid
reagent
cell
prolifer
measur
hthymidin
incorpor
fig
mocktreat
cell
treat
control
nonsilenc
sirna
use
determin
normal
rate
cellular
prolifer
treatment
cisplatin
posit
control
use
inhibit
cell
prolifer
induc
cell
death
previous
observ
silenc
chimera
nm
substanti
inhibit
cell
prolifer
lower
concentr
nm
reduc
effect
cellular
prolifer
sixfold
wherea
secondgener
chimera
still
inhibit
cell
prolifer
low
concentr
fig
correl
cell
arrest
phase
cell
cycl
measur
propidium
iodid
pi
stain
dna
content
flow
cytometri
fig
nocodazol
microtubuledepolymer
drug
use
posit
control
arrest
cell
next
determin
whether
secondgener
chimera
induc
apoptosi
treat
cell
whether
modif
sirna
moieti
increas
apoptot
activ
cell
treat
nm
variou
chimera
absenc
transfect
reagent
cisplatin
use
posit
control
induct
apoptosi
assess
measur
product
activ
caspas
flow
cytometri
tabl
supplementari
fig
expect
modif
introduc
within
sirna
sequenc
greatli
enhanc
cell
death
blunt
chimera
swap
stem
loop
chimera
respect
concentr
nm
swap
stem
loop
chimera
effici
induc
apoptosi
concentr
lower
necessari
chimera
tabl
togeth
data
suggest
modif
made
secondgener
chimera
greatli
enhanc
silenc
well
mitot
catastroph
subsequ
cell
death
next
assess
abil
secondgener
chimera
limit
tumor
growth
athym
mice
bear
tumor
deriv
either
cell
fig
psma
express
tumor
confirm
immunoblot
analysi
supplementari
fig
vivo
experi
compar
cytotox
effect
swap
chimera
blunt
chimera
athym
mice
least
ten
mice
per
treatment
group
subcutan
inject
flank
either
cell
cancer
cell
line
express
luciferas
allow
measur
tumor
growth
use
bioluminesc
imag
fig
supplementari
fig
mice
deriv
tumor
inject
intraperiton
day
total
start
day
either
pb
nmol
indic
chimer
rna
mice
bear
tumor
treat
pb
swap
chimera
differ
tumor
volum
observ
tumor
treatment
either
pb
swap
chimera
indic
swap
chimera
nonspecif
cellkil
effect
fig
pronounc
reduct
tumor
volum
observ
tumor
treat
swap
chimera
fig
contrast
increas
tumor
volum
observ
tumor
treat
pb
nonsilenc
psma
chimera
supplementari
fig
notabl
swaptreat
tumor
complet
regress
end
treatment
remain
fig
see
inset
indic
arrow
repres
tumorbear
mice
growth
rate
tumor
slow
much
fig
although
regress
psmaposit
tumor
evid
swaptreat
mice
tumor
growth
significantli
slow
mice
treat
blunt
chimera
compar
pb
blunt
p
morbid
mortal
observ
follow
treatment
chimer
rna
suggest
compound
toxic
assess
gross
inspect
histolog
analysi
tumor
mice
treat
swap
pb
liquefact
necrosislik
materi
exud
tumor
mass
gross
section
coincid
larg
area
necrosi
commonli
detect
tumor
swap
mice
substanti
less
pbstreat
mice
fig
mitot
cell
detect
group
includ
occasion
larg
unusu
mitot
phenotyp
swaptreat
mice
tunel
stain
seen
throughout
tissu
brown
stain
random
individu
cell
along
interfac
necrot
viabl
tumor
tissu
substanti
differ
tumor
histolog
note
tumor
treat
swap
chimera
versu
pb
control
suggest
nonspecif
uptak
subsequ
process
chimera
occur
system
administr
within
tumor
type
detect
differ
cellular
inflamm
treatment
exampl
pb
versu
swap
moreov
cellular
inflamm
uncommon
mild
immun
cell
detect
along
peripher
border
tumor
compris
mainli
scatter
neutrophil
mononuclear
cell
suggest
tumor
regress
depend
immun
respons
addit
measur
immun
respons
serum
treat
mice
screen
level
use
enzymelink
immunosorb
assay
elisa
fig
differ
seen
cytokin
level
mice
treat
either
pb
swap
chimera
contrast
mice
treat
polyinosin
polycytidyl
acid
poli
c
establish
immun
stimul
data
suggest
chimera
trigger
innat
immun
respons
may
safe
vivo
applic
determin
whether
sirna
releas
chimera
inde
trigger
rnai
vivo
perform
modifi
rapid
amplif
cdna
end
race
pcr
previous
describ
mrna
tumor
anim
treat
indic
chimera
fig
sequenc
product
gener
primer
demonstr
cleavag
occur
base
rel
guid
sirna
strand
pcr
product
observ
sampl
controltr
tumor
result
confirm
specif
sirnamedi
cleavag
product
mrna
treat
tumor
vivo
next
determin
whether
addit
kda
polyethylen
glycol
peg
group
could
extend
circul
halflif
swap
chimera
without
affect
bind
psma
supplementari
fig
silenc
activ
supplementari
fig
kda
peg
place
end
sirna
passeng
strand
chemic
synthesi
rna
strand
includ
decreas
nucleas
sensit
analog
fulli
chimera
termin
peg
use
control
supplementari
fig
first
verifi
addit
peg
abrog
bind
specif
intern
psmaposit
prostat
cancer
cell
supplementari
fig
confirm
silenc
mrna
pegmodifi
chimera
supplementari
fig
determin
vivo
halfliv
chimera
rna
intraperiton
inject
mice
blood
sampl
obtain
min
h
h
h
later
qrtpcr
use
quantifi
amount
rna
present
blood
sampl
vivo
circul
halflif
chimera
substanti
increas
min
h
addit
kda
peg
fig
left
panel
next
address
whether
pegyl
swap
chimera
lead
increas
vivo
efficaci
mice
bear
tumor
intraperiton
inject
low
dose
pmol
f
chimera
pb
total
inject
perform
cours
tumor
volum
determin
figur
chimera
inhibit
tumor
growth
substanti
lower
dose
fig
e
right
panel
nmol
versu
pmol
determin
whether
inhibit
tumor
growth
treat
mice
correl
silenc
gene
express
chimera
fig
left
panel
mrna
express
significantli
reduc
swap
p
p
tumor
compar
pb
control
determin
whether
prolong
silenc
gene
express
might
respons
differ
vivo
efficaci
chimera
fig
carri
pharmacodynam
studi
assess
silenc
time
fig
right
panel
experi
psma
posit
tumorbear
mice
inject
two
dose
apart
nmol
either
quantit
rtpcr
perform
mrna
tumor
determin
amount
mrna
treat
tumor
indic
time
point
mrna
silenc
observ
fpegtreat
tumor
h
tumor
last
treatment
fig
right
panel
data
indic
chimera
greater
gene
silenc
activ
vivo
develop
character
aptamersirna
chimera
enhanc
activ
specif
vivo
kinet
rel
firstgener
chimera
rnaonli
chimera
optim
incorpor
modif
shown
enhanc
silenc
activ
specif
sirna
modif
appli
firstgener
chimera
includ
addit
nt
optim
thermodynam
profil
structur
duplex
favor
risc
process
correct
sirna
guid
strand
target
approach
treat
prostat
cancer
effect
deliv
system
amen
chemic
synthesi
largescal
product
mani
potenti
therapeut
applic
chimera
includ
cancer
therapi
requir
system
administr
therapeut
reagent
also
necessari
optim
vivo
kinet
chimera
addit
enhanc
potenc
specif
termin
modif
rna
peg
increas
halflif
bioavail
mani
oligonucleotidebas
therapi
includ
rna
aptam
found
addit
kda
peg
smaller
rna
strand
promot
increas
retent
chimera
serum
fig
without
affect
chimera
target
silenc
supplementari
fig
pegyl
reagent
lead
prolongedsilenc
vivo
fig
right
panel
inhibit
tumor
growth
lower
dose
mice
bear
psmaposit
prostat
tumor
fig
right
panel
although
possibl
greater
degre
silenc
induc
pegyl
chimera
time
point
result
prolong
exposur
tumor
reagent
altern
possibl
differ
due
linger
effect
greater
initi
knockdown
previous
describ
firstgener
chimera
cellular
target
optim
chimer
rna
mediat
interact
aptam
portion
chimera
psma
express
surfac
prostat
cancer
cell
fig
found
first
nt
psma
aptam
suffici
target
chimera
psma
express
surfac
prostat
cancer
cell
allow
us
truncat
aptam
portion
chimera
nt
nt
without
loss
function
fig
chimera
design
short
aptam
long
strand
base
length
effici
produc
chemic
synthesi
deplet
optim
chimera
also
specif
psmaposit
prostat
cancer
cell
data
shown
result
decreas
prolifer
increas
apoptosi
target
cell
cultur
fig
tabl
supplementari
fig
notabl
modif
sirna
portion
chimera
effect
observ
concentr
reagent
lower
firstgener
chimera
fig
tabl
addit
found
upon
deplet
prostat
cancer
cell
undergo
mitot
arrest
fig
lead
apoptosi
coincid
observ
reduc
express
report
lead
mitot
catastroph
crisi
due
arrest
cancer
cell
transit
cell
cycl
death
prostat
cancer
cell
notabl
effect
specif
cancer
cell
normal
cell
resum
cellcycl
entri
upon
restor
express
addit
measur
specif
achiev
modifi
sirna
portion
chimera
enhanc
load
guid
strand
risc
fig
optim
load
guid
strand
risc
thought
reduc
offtarget
effect
result
inappropri
incorpor
sirna
strand
silenc
complex
although
rule
potenti
offtarget
effect
mediat
guid
strand
effect
would
like
restrict
tumor
sirna
target
psmaexpress
prostat
cancer
cell
fig
major
advantag
chimera
approach
therapeut
advanc
prostat
cancer
lie
target
specif
achiev
level
aptam
psmaexpress
cell
specif
target
level
sirna
sirna
design
cancerspecif
transcript
cancer
cellspecif
target
could
substanti
reduc
amount
sirna
need
effect
therapi
reduc
system
cytotox
target
deliveri
approach
sirna
describ
date
involv
use
complex
formul
synthet
polym
protein
charg
peptid
although
approach
prove
effect
preclin
studi
multicompon
formul
complic
product
safeti
assess
onecompon
system
involv
direct
conjug
sirna
rna
aptam
reduc
complex
reagent
thu
simplifi
manufactur
chimera
increas
vivo
stabil
decreas
immunotox
termin
kda
peg
increas
serum
retent
modif
well
character
human
report
well
toler
littl
toxic
rna
oligonucleotid
similar
modif
alreadi
approv
use
human
exampl
macugen
mani
quickli
move
clinic
pipelin
although
complet
rule
potenti
intracellular
toxic
fluoropyrimidinemodifi
rna
lead
nonspecif
immunostimul
base
find
fig
expect
chimera
produc
problemat
toxic
human
principl
aptamersirna
chimera
approach
appli
develop
reagent
target
mani
differ
cell
type
provid
celltypespecif
receptor
exist
aptam
receptor
select
develop
aptamersirna
chimera
target
hivinfect
cell
support
notion
type
modif
enabl
vivo
efficaci
chimera
may
thu
prove
use
develop
sirnabas
therapeut
wide
varieti
diseas
method
associ
refer
avail
onlin
version
paper
http
wwwnaturecomnaturebiotechnolog
refer
web
version
pubm
central
supplementari
materi
optim
chimera
blunt
truncat
version
firstgener
chimera
describ
previous
aptam
portion
chimera
truncat
nt
nt
ovh
overhang
chimera
similar
blunt
nt
uu
overhang
end
sirna
duplex
gu
gu
wobbl
chimera
ident
ovh
wobbl
base
pair
end
antisens
sirna
strand
silencingguid
strand
swap
sens
antisens
strand
sirna
duplex
revers
stem
loop
hairpin
chimera
sirna
duplex
stem
continu
aptam
loop
structur
predict
gener
use
rnastructur
v
bind
truncat
version
psma
aptam
optim
chimera
cell
express
psma
rna
endlabel
p
lncap
cell
cell
incub
either
fulllength
psma
aptam
nt
truncat
version
psma
aptam
nt
nt
plabel
boundintern
rna
determin
liquid
scintil
counter
lsc
filter
bind
assay
data
shown
b
rel
affin
psma
aptam
truncat
aptam
cell
express
psma
vari
amount
nm
endlabel
incub
fix
lncap
cell
bound
count
determin
filter
bind
assay
c
firstgener
chimera
optim
chimera
incub
either
cell
black
bar
lncap
cell
process
bound
count
determin
lsc
analysi
chimera
process
rnai
machineri
vitro
dicer
process
plabel
chimera
incub
recombin
human
dicer
enzym
either
h
dicer
cleavag
uncleav
dicer
product
visual
nondenatur
page
b
assess
strand
bia
load
sirna
silenc
strand
risc
small
fragment
northern
blot
rna
isol
cell
transfect
pmol
optim
aptamersirna
chimera
construct
load
sirna
silenc
strand
risc
protect
sirna
strand
degrad
detect
specif
probe
use
modifi
northern
blot
assay
strand
load
rapidli
degrad
rna
use
load
control
duplex
sirna
duplex
firstgener
chimera
blunt
ovh
gu
swap
stem
loop
chimera
describ
figur
probe
control
show
hybrid
effici
sens
antisens
probe
vari
intens
unprocess
chimera
upper
band
blot
due
differenti
probe
bind
speci
reflect
amount
trend
observ
equal
amount
chimera
directli
load
gel
process
describ
data
shown
vivo
efficaci
optim
psma
chimera
xenograft
model
prostat
cancer
luciferaseexpress
psmaposit
psmaneg
prostat
cancer
cell
inject
flank
nude
nunu
mice
week
treatment
optim
chimera
treatment
optim
chimera
commenc
tumor
reach
volum
cm
nmol
either
blunt
swap
administ
intraperiton
mice
bear
tumor
control
specif
mous
xenograft
model
prostat
cancer
bear
psmaneg
prostat
cancer
cell
also
treat
swap
chimera
total
ten
treatment
administ
treatment
group
treatment
occur
everi
day
consecut
day
tumor
measur
calip
everi
day
cours
experi
salin
pb
treat
anim
use
control
anim
euthan
last
treatment
n
mice
per
treatment
group
bottom
panel
bioluminesc
imag
prostat
tumor
carri
treatment
optim
chimera
day
exampl
show
tumor
growth
four
